United Therapeutics (UTHR) Depreciation and Depletion (2024 - 2026)

United Therapeutics has disclosed Depreciation and Depletion across 3 years of filings, most recently posting $21.6 million for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $21.6 million, up 10.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.7 million (up 13.48% YoY), and the FY2025 annual result was $84.7 million, up 18.3% from the prior year.
• Depreciation and Depletion came in at $21.6 million for Q1 2026 at United Therapeutics, down from $22.7 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $22.7 million in Q4 2025 to a low of $14.8 million in Q1 2024.
• The 3-year median for Depreciation and Depletion is $19.6 million (2025), against an average of $19.8 million.
• Across the five-year window, Depreciation and Depletion surged 32.43% in 2025 and gained 10.2% in 2026, its largest moves.
• United Therapeutics' Depreciation and Depletion stood at $19.4 million in 2024, then increased by 17.01% to $22.7 million in 2025, then decreased by 4.85% to $21.6 million in 2026.
• The last three Depreciation and Depletion figures came in at $21.6 million (Q1 2026), $22.7 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.